Celldex is a clinical-stage biotech advancing barzolvolimab through Phase 3, with R&D spending nearly doubling from $30.9M in 2024Q1 to $67.5M in 2026Q2. The company has no product revenue, and its cash position of $47.5M covers less than one quarter of operat...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.94+11.3% vs -$1.06 | $22,000-97.0% vs $734,917 |
Q2 2026 May 7, 2026 | -$1.18-2.9% vs -$1.15 | $15,000-98.1% vs $795,364 |
Q1 2026 Feb 25, 2026 | -$1.22-22.0% vs -$1.00 | $100,000-92.4% vs $1M |
Q4 2025 Nov 10, 2025 | -$1.01-14.8% vs -$0.88 | — vs $985,818 |
Engineers Gate Manager LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ: CLDX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,842 shares of the biopharmaceutical company's stock, valued at approximately $1,259,000. A number of other institutional investors have
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Profitability This table compares Celldex Therapeutics and Precigen's
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Seres Therapeutics (NASDAQ: MCRB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Profitability This table compares Celldex Therapeutics and Seres
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
Benchmark CLDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Celldex Therapeutics, Inc. (CLDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.12 | $2.07B | -7.98 | -78.63% | -17253.33% | -40.62% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $3.48 | $859.66M | -13.38 | 22.09% | -12.35% | -36% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — |
Celldex Therapeutics, Inc. (CLDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Celldex Therapeutics, Inc. (CLDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 15, 2026·SEC
Jun 26, 2026·SEC
Get notified when CLDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Celldex Therapeutics, Inc. (CLDX) stock FAQ — growth, dividends, profitability & financials explained
Celldex Therapeutics, Inc. (CLDX) reported $0.1M in revenue for fiscal year 2025. This represents a 90% decrease from $1.1M in 1996.
Celldex Therapeutics, Inc. (CLDX) saw revenue decline by 78.6% over the past year.
Celldex Therapeutics, Inc. (CLDX) reported a net loss of $300.6M for fiscal year 2025.
Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -40.6%. Negative ROE indicates the company is unprofitable.
Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $241.8M in fiscal year 2025, likely due to heavy capital investments.
